Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Post by gdown9on Oct 12, 2018 8:27pm
92 Views
Post# 28792796

Veritas kicks off coverage of Canada's cannabis industry

Veritas kicks off coverage of Canada's cannabis industryhttps://ca.proactiveinvestors.com/companies/news/207016/veritas-kicks-off-coverage-of-canada-s-cannabis-industry-with-sell-ratings-canopy-growth-aphria-aurora-cannabis-and-cronos-207016.html

"
A pessimistic stock analyst from Veritas Investment Research is initiating his coverage of Canada’s cannabis stocks with four Sell ratings on Canopy Growth (NYSE:CGC), Aphria (OTCMKTS:APHQF),  Aurora Cannabis (OTCMKTS:ACBFF) and Cronos Group (NASDAQ:CRON).

Move onto Aphria and Rolfe takes a more sympathetic view, calling the company a “star unicorn” and praising its useful disclosure on strategies and operations. Rolphe says Aphria’s focus on cost management, cash-flow generation and accounting bodes well for its performance. He also thinks Aphria is “best positioned” to become a takeout candidate if industry consolidation gathers pace. Rolfe sets its price target at C$19.
"


Bullboard Posts